nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2010-14-3-32-36nefr-1227Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESПРОБЛЕМА СООТНОШЕНИЯ ПОЛЬЗЫ И РИСКА ТЕРАПИИ СРЕДСТВАМИ, СТИМУЛИРУЮЩИМИ ЭРИТРОПОЭЗ, ПРИ ДИАБЕТИЧЕСКОЙ НЕФРОПАТИИPROBLEM OF THE THERAPY USE AND RISK RATIO OF THE MEDICATION WHICH STIMULATE ERTHROPOESIS IN DIABETIC NEPHROPATHYПчелинИ. Ю.PchelinI. Yu.

кафедра факультетской терапии медицинского факультета

197227, Санкт-Петербург, СПбГУ, медицинскиий факультет, пр. Испытателей, д. 6., к. 1, кв. 112; Тел.: +79213614700.

ewan2008@bk.ruШишкинА. Н.ShishkinA. N.

кафедра факультетской терапии медицинского факультета

КоробицынЛ. П.KorobitsynL. P.Санкт-Петербургский государственный университет, г.Санкт-ПетербургРоссияСанкт-Петербургский государственный университет, г. Санкт-ПетербургРоссияООО ”Протеиновый контур”, г. Санкт-ПетербургРоссия2010100320101433236Copyright © Пчелин И.Ю., Шишкин А.Н., Коробицын Л.П., 20102010Пчелин И.Ю., Шишкин А.Н., Коробицын Л.П.Pchelin I.Y., Shishkin A.N., Korobitsyn L.P.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/1227

Более 20 лет для коррекции анемии у пациентов с хронической болезнью почек (ХБП) применяются средства, стимулирующие эритропоэз (ССЭ). В настоящее время в России доступно несколько препаратов из группы ССЭ: эпоэтин-α (эпокрин, эральфон, эпрекс), эпоэтин-β (рекормон), эпоэтин-ω (эпомакс), дарбэпоэтин-α (аранесп), пегилированный эпоэтин-β (мирцера). Несмотря на то, что изучению эффективности терапии ССЭ и её влияния на прогрессирование ХБП и сердечно-сосудистых осложнений было посвящено большое количество исследований, до сих пор отсутствует единое мнение относительно показаний к проведению терапии ССЭ, оптимальных терапевтических схем и целевых уровней гемоглобина.

For more than 20 years to correct anemia in patients with chronic kidney disease (CKD) are used medications which stimulate erythropoesis (MSE). Currently in Russia there are multiple preparations of the MSE group: epoetin-α (epokrin, eralfon, Eprex), epoetin-β (Recormon), epoetin-ω (epomaks), darbepoetin-α (Aranesp), pegylated epoetin-β (Mircera ). Despite the fact that the study of the effectiveness of therapy MSE and its impact on the progression of CKD and cardiovascular disease was the subject of many studies, there is still no consensus regarding indications for treatment of MSE, the optimal therapeutic regimen and target hemoglobin levels.

анемияхроническая болезнь почекдиабетическая нефропатияэритропоэтинстимуляторы эритропоэзапобочные эффектыanemiachronic kidney diseasediabetic nephropathyerythropoietinerythropoesis stimulantsside effectsReferencesElliott S, Pham E, Macdougall IC. Erythropoietins: A common mechanism of action. Exp Hematol 2008; 36: 1573-1584Elliott S, Pham E, Macdougall IC. Erythropoietins: A common mechanism of action. Exp Hematol 2008; 36: 1573-1584Шестакова МВ, Дедов ИИ. Сахарный диабет и хроническая болезнь почек. ООО «Медицинское информационное агентство», М., 2009; 355-358Шестакова МВ, Дедов ИИ. Сахарный диабет и хроническая болезнь почек. ООО «Медицинское информационное агентство», М., 2009; 355-358Kestenbaum B, Kimmel PL, Malozowski S et al. Reevaluating erythropoiesis-stimulating agents. N Engl J Med 2010; 362: 1742-1743Kestenbaum B, Kimmel PL, Malozowski S et al. Reevaluating erythropoiesis-stimulating agents. N Engl J Med 2010; 362: 1742-1743Bosman DR, Winkler AS, Marsden JT et al. Anaemia associated with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24: 495-499Bosman DR, Winkler AS, Marsden JT et al. Anaemia associated with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24: 495-499Thomas MC, MacIsaac RJ, Tsalamandris C et al. Unrecognized Anemia in Patients with Diabetes: A cross-sectional survey. Diabetes Care 2003; 26: 1164-1169Thomas MC, MacIsaac RJ, Tsalamandris C et al. Unrecognized Anemia in Patients with Diabetes: A cross-sectional survey. Diabetes Care 2003; 26: 1164-1169McGill JB, Bell DSH. Anemia and the role of erythropoietin in diabetes. J Diabetes Complications 2006; 20: 262-272McGill JB, Bell DSH. Anemia and the role of erythropoietin in diabetes. J Diabetes Complications 2006; 20: 262-272McCullough PA, Bakris GL, Owen WF. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J 2004; 48: 243-251McCullough PA, Bakris GL, Owen WF. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J 2004; 48: 243-251Najafian B, Mauer M. Progression of diabetic nephropathy in type 1 diabetic patients. Diabetes Res Clin Pract 2009; 83: 1-8Najafian B, Mauer M. Progression of diabetic nephropathy in type 1 diabetic patients. Diabetes Res Clin Pract 2009; 83: 1-8Hahr AJ, Molitch ME. Diabetes, Cardiovascular Risk and Nephropathy. Cardiol Clin 2010. In pressHahr AJ, Molitch ME. Diabetes, Cardiovascular Risk and Nephropathy. Cardiol Clin 2010. In pressConti AA, Minelli M, Gensini GF. Global management of high risk patients: Integrated primary cardiovascular prevention in diabetics. International Congress Series 2007; 1303: 10-20Conti AA, Minelli M, Gensini GF. Global management of high risk patients: Integrated primary cardiovascular prevention in diabetics. International Congress Series 2007; 1303: 10-20Pfeffer MA, Burdmann EA, Chen CY et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2009; 54: 59-69Pfeffer MA, Burdmann EA, Chen CY et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2009; 54: 59-69Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032Wright RJ, Kanagasundaram NS, Quinton R et al. Darbepoetin alfa and chronic kidney disease. N Engl J Med 2010; 362: 653-654Wright RJ, Kanagasundaram NS, Quinton R et al. Darbepoetin alfa and chronic kidney disease. N Engl J Med 2010; 362: 653-654Marsden PA. Treatment of Anemia in Chronic Kidney Disease — Strategies Based on Evidence. N Engl J Med 2009; 361: 2089-2090Marsden PA. Treatment of Anemia in Chronic Kidney Disease — Strategies Based on Evidence. N Engl J Med 2009; 361: 2089-2090Drueke TB, Locatelli F, Clyne N et al. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. N Engl J Med 2006; 355: 2071-2084Drueke TB, Locatelli F, Clyne N et al. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. N Engl J Med 2006; 355: 2071-2084Singh AK, Szczech L, Tang KL et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N Engl J Med 2006; 355: 2085-2098Singh AK, Szczech L, Tang KL et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N Engl J Med 2006; 355: 2085-2098Zoppini G, Targher G, Chonchol M et al. Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. Atherosclerosis 2010; 210: 575-580Zoppini G, Targher G, Chonchol M et al. Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. Atherosclerosis 2010; 210: 575-580Joss N, Patel R, Paterson K et al. Anaemia is common and predicts mortality in diabetic nephropathy. QJM 2007; 100: 641-647Joss N, Patel R, Paterson K et al. Anaemia is common and predicts mortality in diabetic nephropathy. QJM 2007; 100: 641-647Unger EF, Thompson AM, Blank MJ. Erythropoiesis-Stimulating Agents – Time for a reevaluation. N Engl J Med 2010; 362: 189-192Unger EF, Thompson AM, Blank MJ. Erythropoiesis-Stimulating Agents – Time for a reevaluation. N Engl J Med 2010; 362: 189-192Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1082-1088Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1082-1088Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: Time to reach the full therapeutic potential of erythropoietin. Biochim Biophys Acta 2007; 1776: 1-9Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: Time to reach the full therapeutic potential of erythropoietin. Biochim Biophys Acta 2007; 1776: 1-9Ruifrok WT, Boer RA, Westenbrink BD et al. Erythropoietin in cardiac disease: New features of an old drug. Eur J Pharmacol 2008; 585: 270-277Ruifrok WT, Boer RA, Westenbrink BD et al. Erythropoietin in cardiac disease: New features of an old drug. Eur J Pharmacol 2008; 585: 270-277Miura T, Miki T, Nishihara M et al. Molecular mechanisms of cardiomyocyte protection against ischemia/reperfusion injury by erythropoietin (EPO) receptor activation. J Mol Cell Cardiol 2006; 41: 1043-1044Miura T, Miki T, Nishihara M et al. Molecular mechanisms of cardiomyocyte protection against ischemia/reperfusion injury by erythropoietin (EPO) receptor activation. J Mol Cell Cardiol 2006; 41: 1043-1044Cooij MA, Groenendaal F, Kavelaars A et al. Neuroprotective properties and mechanisms of erythropoietin in ‘in vitro’ and ‘in vivo’ experimental models for hypoxia/ischemia. Brain Res Rev 2008; 59: 22-33Cooij MA, Groenendaal F, Kavelaars A et al. Neuroprotective properties and mechanisms of erythropoietin in ‘in vitro’ and ‘in vivo’ experimental models for hypoxia/ischemia. Brain Res Rev 2008; 59: 22-33Pallet N, Bouvier N, Legendre C et al. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res 2010; 61: 71-75Pallet N, Bouvier N, Legendre C et al. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res 2010; 61: 71-75Wang W, Zhang J. Protective effect of erythropoietin against aristolochic acid-induced apoptosis in renal tubular epithelial cells. Eur J Pharmacol 2008; 588: 135-140Wang W, Zhang J. Protective effect of erythropoietin against aristolochic acid-induced apoptosis in renal tubular epithelial cells. Eur J Pharmacol 2008; 588: 135-140Chang YK, Choi DE, Na KR et al. Erythropoietin Attenuates Renal Injury in an Experimental Model of Rat Unilateral Ureteral Obstruction via Anti-Inflammatory and Anti-Apoptotic effects. J Urol 2009; 181: 1434-1443Chang YK, Choi DE, Na KR et al. Erythropoietin Attenuates Renal Injury in an Experimental Model of Rat Unilateral Ureteral Obstruction via Anti-Inflammatory and Anti-Apoptotic effects. J Urol 2009; 181: 1434-1443Sekiguchi N, Inoguchi T, Kobayashi K et al. Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells. Biochem Biophys Res Commun 2005; 34: 218-222Sekiguchi N, Inoguchi T, Kobayashi K et al. Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells. Biochem Biophys Res Commun 2005; 34: 218-222Quin C, Xiao Y, Zhong Q et al. Anti-inflammatory effect of erythropoietin pretreatment on cardiomyocytes with hypoxia/reoxygenation injury and the possible mechanism. Chin J Traumatol 2008; 11: 352-358Quin C, Xiao Y, Zhong Q et al. Anti-inflammatory effect of erythropoietin pretreatment on cardiomyocytes with hypoxia/reoxygenation injury and the possible mechanism. Chin J Traumatol 2008; 11: 352-358Hirata A, Minamino T, Asanuma H et al. Erythropoietin Enhances Neovascularization of Ischemic Myocardium and Improves Left Ventricular Dysfunction After Myocardial Infarction in Dogs. J Am Coll Cardiol 2006; 48: 176-184Hirata A, Minamino T, Asanuma H et al. Erythropoietin Enhances Neovascularization of Ischemic Myocardium and Improves Left Ventricular Dysfunction After Myocardial Infarction in Dogs. J Am Coll Cardiol 2006; 48: 176-184Lykissas MG, Sakellariou E, Vekris MD et al. Axonal regeneration stimulated by erythropoietin: An experimental study in rats. J Neurosci Methods 2007; 164: 107-115Lykissas MG, Sakellariou E, Vekris MD et al. Axonal regeneration stimulated by erythropoietin: An experimental study in rats. J Neurosci Methods 2007; 164: 107-115Vaziri ND. Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol and Hypertens 2001; 10: 633-637Vaziri ND. Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol and Hypertens 2001; 10: 633-637Zhang Z, Barrett JD, Jamgotchian N et al. Recombinant human erythropoietin (rhEPO) stimulates gene transcription of renin angiotensin system and growth factor mRNAs in rat vascular smooth muscle cells [abstract]. J Investig Med 1996; 44: 91Zhang Z, Barrett JD, Jamgotchian N et al. Recombinant human erythropoietin (rhEPO) stimulates gene transcription of renin angiotensin system and growth factor mRNAs in rat vascular smooth muscle cells [abstract]. J Investig Med 1996; 44: 91Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33: 821-828Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33: 821-828Akimoto T, Kuzano E, Fujita N et al. Erythropoietin modulates angiotensin II-or noradrenaline-induced Ca2+ mobilization in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant 2001; 16: 491-499Akimoto T, Kuzano E, Fujita N et al. Erythropoietin modulates angiotensin II-or noradrenaline-induced Ca2+ mobilization in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant 2001; 16: 491-499Vogel V, Kramer HJ, Bдcker A et al. Effects of Erythropoietin on Endothelin-1 Synthesis and the Cellular Calcium Messenger System in Vascular Endothelial Cells. Am J Hypertens 1997; 10: 289-296Vogel V, Kramer HJ, Bдcker A et al. Effects of Erythropoietin on Endothelin-1 Synthesis and the Cellular Calcium Messenger System in Vascular Endothelial Cells. Am J Hypertens 1997; 10: 289-296Eckardt KU. Erythropoietin and microvascular diabetic complications. Nephrol Dial Transplant 2009; 24: 388-390Eckardt KU. Erythropoietin and microvascular diabetic complications. Nephrol Dial Transplant 2009; 24: 388-390Nagarajan S, Mansfield E, Hsieh S et al. Transplant reno-vascular stenoses associated with early erythropoietin use. Clin Transplant 2007; 21: 597-608Nagarajan S, Mansfield E, Hsieh S et al. Transplant reno-vascular stenoses associated with early erythropoietin use. Clin Transplant 2007; 21: 597-608Fuste B, Seradell M, Escolar G et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 687-685Fuste B, Seradell M, Escolar G et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 687-685Kahraman S, Yilmaz R, Kirkpantur A et al. Impact of rhEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology 2005; 10: 64-69Kahraman S, Yilmaz R, Kirkpantur A et al. Impact of rhEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology 2005; 10: 64-69Гуревич КЯ, ред. Человеческий рекомбинантный эритропоэтин (Эпокрин) в лечении анемии (Практическое руководство). ИКФ «Фолиант», СПб., 2001; 45-46Гуревич КЯ, ред. Человеческий рекомбинантный эритропоэтин (Эпокрин) в лечении анемии (Практическое руководство). ИКФ «Фолиант», СПб., 2001; 45-46Пчелин И. Ю, Шишкин А Н. Механизмы развития и клиническое значение анемии у пациентов с сахарным диабетом 1 и 2 типа. Вестн С.-Петерб ун-та Сер 11 2010; (2): 73-80Пчелин И. Ю, Шишкин А Н. Механизмы развития и клиническое значение анемии у пациентов с сахарным диабетом 1 и 2 типа. Вестн С.-Петерб ун-та Сер 11 2010; (2): 73-80Kazory A, Ross EA. Anemia: The Point of Convergence or Divergence for Kidney Disease and Heart Failure? J Am Coll Cardiol 2009; 53: 639-647Kazory A, Ross EA. Anemia: The Point of Convergence or Divergence for Kidney Disease and Heart Failure? J Am Coll Cardiol 2009; 53: 639-647Kleijn L, Boer RA, Voors AA. Should erythropoietin treatment in chronic heart failure be haemoglobin targeted? Eur J Heart Fail 2010; 12: 215-216Kleijn L, Boer RA, Voors AA. Should erythropoietin treatment in chronic heart failure be haemoglobin targeted? Eur J Heart Fail 2010; 12: 215-216Goldsmith D, Covic A. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). Nephrol Dial Transplant 2010. In pressGoldsmith D, Covic A. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). Nephrol Dial Transplant 2010. In press

The authors declare that there are no conflicts of interest present.